Elena Gonzalez-Rodriguez1,2, Bérengère Aubry-Rozier3, Delphine Stoll3, Khalil Zaman4, Olivier Lamy3,5. 1. Center of Bone Diseases, Service of Rheumatology, CHUV, Lausanne University Hospital and University of Lausanne, Rue Pierre-Decker 4, 1011, Lausanne, Switzerland. elena.gonzalez-rodriguez@chuv.ch. 2. Service of Endocrinology, Diabetes and Metabolism, CHUV, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. elena.gonzalez-rodriguez@chuv.ch. 3. Center of Bone Diseases, Service of Rheumatology, CHUV, Lausanne University Hospital and University of Lausanne, Rue Pierre-Decker 4, 1011, Lausanne, Switzerland. 4. Breast Center, CHUV, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. 5. Service of Internal Medicine, CHUV, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Abstract
PURPOSE: At denosumab discontinuation, bone turnover markers increase and the gained BMD is lost. In postmenopausal osteoporosis, there is an increased risk of spontaneous vertebral fractures (VFs) of about 1 to 10%, rarely described in women under denosumab for aromatase inhibitors (AI)-treated breast cancer. We aim to describe the characteristics of 15 patients under denosumab given for AI-treated early-stage breast cancer that presented VFs at its discontinuation. METHODS: Single-center retrospective case series of 15 patients. We report clinical data, dual X-ray absorptiometry values at denosumab initiation and discontinuation, and serum B-crosslaps dosage at the time of VF occurrence (before denosumab resumption). RESULTS: Fifteen women (66.4 ± 7.1 years at denosumab discontinuation) that received AI for 5.0 ± 0.6 years, denosumab 60 mg for 8.2 ± 2.0 doses, and developed 60 VFs at denosumab discontinuation, were followed for 24.4 ± 9.5 months. Patients suffered from 1 to 11 (mean 4.0 ± 1.9) clinical VFs within 7 to 16 months after last denosumab injection. VFs developed earlier in patients with longer denosumab treatment (R2 = 0.29, p = 0.04) and in patients without osteoporosis before denosumab (9.4 ± 2.0 vs. 13.0 ± 2.0 months; p = 0.005). Serum B-crosslaps at the time of VFs tended to be higher in patients with earlier VFs (R2 = 0.47; p = 0.06) or with longer denosumab treatment (R2 = 0.48; p = 0.06). Denosumab was resumed in all patients, then switched for a bisphosphonate in eight. No new VFs occurred during follow-up. CONCLUSIONS: Despite an apparently low fracture risk, women under denosumab for AI-treated early-stage breast cancer develop spontaneous VFs at denosumab discontinuation. This risk increases with treatment duration and may be prevented by a potent bisphosphonate.
PURPOSE: At denosumab discontinuation, bone turnover markers increase and the gained BMD is lost. In postmenopausal osteoporosis, there is an increased risk of spontaneous vertebral fractures (VFs) of about 1 to 10%, rarely described in women under denosumab for aromatase inhibitors (AI)-treated breast cancer. We aim to describe the characteristics of 15 patients under denosumab given for AI-treated early-stage breast cancer that presented VFs at its discontinuation. METHODS: Single-center retrospective case series of 15 patients. We report clinical data, dual X-ray absorptiometry values at denosumab initiation and discontinuation, and serum B-crosslaps dosage at the time of VF occurrence (before denosumab resumption). RESULTS: Fifteen women (66.4 ± 7.1 years at denosumab discontinuation) that received AI for 5.0 ± 0.6 years, denosumab 60 mg for 8.2 ± 2.0 doses, and developed 60 VFs at denosumab discontinuation, were followed for 24.4 ± 9.5 months. Patients suffered from 1 to 11 (mean 4.0 ± 1.9) clinical VFs within 7 to 16 months after last denosumab injection. VFs developed earlier in patients with longer denosumab treatment (R2 = 0.29, p = 0.04) and in patients without osteoporosis before denosumab (9.4 ± 2.0 vs. 13.0 ± 2.0 months; p = 0.005). Serum B-crosslaps at the time of VFs tended to be higher in patients with earlier VFs (R2 = 0.47; p = 0.06) or with longer denosumab treatment (R2 = 0.48; p = 0.06). Denosumab was resumed in all patients, then switched for a bisphosphonate in eight. No new VFs occurred during follow-up. CONCLUSIONS: Despite an apparently low fracture risk, women under denosumab for AI-treated early-stage breast cancer develop spontaneous VFs at denosumab discontinuation. This risk increases with treatment duration and may be prevented by a potent bisphosphonate.
Authors: Olatundun D Awosanya; Ushashi C Dadwal; Erik A Imel; Qigui Yu; Melissa A Kacena Journal: Curr Osteoporos Rep Date: 2022-06-20 Impact factor: 5.163
Authors: Francisco Torres-Naranjo; Pilar De la Peña-Rodríguez; Roberto Enrique López-Cervantes; Jorge Morales-Torres; Jorge Morales-Vargas; Hugo Gutiérrez-Hermosillo; Alan Christopher Guzmán-Rico; Roberto Gabriel González-Mendoza; Pedro Nel Rueda Plata; Miguel Flores Castro; Cuauhtémoc Celis Gonzalez; Rolando Espinosa Morales; Sergio Quintero Hernández; Juan Ricardo López-Taylor Journal: Arch Osteoporos Date: 2021-01-25 Impact factor: 2.617
Authors: Komal Waqas; Joana Lima Ferreira; Elena Tsourdi; Jean-Jacques Body; Peyman Hadji; M C Zillikens Journal: J Bone Oncol Date: 2021-03-18 Impact factor: 4.072